Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rumex crispus pollen is a biologic allergenic extract derived from the pollen of the *Rumex crispus* plant, commonly known as curly or yellow dock. [1] It was approved for use in the United States in 1941. [4] The extract is used for both diagnostic purposes (allergenic skin testing) and for therapeutic hyposensitization (immunotherapy) in individuals with allergic reactions to this specific pollen. [1] Immunotherapy involves administering the extract via subcutaneous injection to gradually expose the immune system to the allergen, with the goal of reducing allergic sensitivity over time. [1] One product containing this extract was "Center-al - Rumex Crispus Pollen," developed and distributed by ALK-Abelló, Inc. This product has since been discontinued, with its NDC listing expiring in 2023.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rumex crispus pollen.